RT Journal Article SR Electronic T1 Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014 JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.141156 DO 10.3899/jrheum.141156 A1 William Tillett A1 Lihi Eder A1 Niti Goel A1 Maarten De Wit A1 Dafna D. Gladman A1 Oliver FitzGerald A1 Willemina Campbell A1 Philip S. Helliwell A1 Laure Gossec A1 Ana-Maria Orbai A1 Alexis Ogdie A1 Vibeke Strand A1 Neil J. McHugh A1 Philip J. Mease YR 2015 UL http://www.jrheum.org/content/early/2015/04/27/jrheum.141156.abstract AB Objective To discuss the need for revision of the “core set” of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework. Methods The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting. Results Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100%), and the inclusion of disease impact (94%) and fatigue (72%) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as “inflammatory musculoskeletal disease,” and nail and skin psoriasis as “psoriasis activity.” Conclusion Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.